Found 37 Lymphoma trials
A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
This is an observational study to determine what types of medications patients take to treat MCL as well as how patients respond to those medications.
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
UPCC 09421 Single-Arm Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma
UPCC 45418: An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib in Combination with Everolimus in Subjects with Relapsed/Refractory Classical Hodgkin Lymphoma
The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.
UPCC 39418: A Phase II Single Arm Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) In Adult Patients with Refractory or Relapsed Follicular Lymphoma
To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.
A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the …
Please choose between Voice or SMS based delivery of verification code
or